It is interesting to draw analogies between TKIs targeting EGFR and TKIs specific to BCR-ABL1, a fusion tyrosine kinase that acts as the driver of chronic myeloid leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.